Navigation Links
ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
Date:10/17/2011

treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors.  Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, CCX282-B (Traficet-EN, now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. ChemoCentryx's lead independent drug candidate, CCX140-B, a CCR2 antagonist, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetes. CCX140-B is expected to enter Phase II clinical development for the treatment of diabetic nephropathy in 2011. Other clinical programs include CCX354, a CCR1 antagonist which recently completed a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, in Phase II clinical development for the treatment of vasculitis; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoCentryx also has several programs in advanced preclinical development.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy o
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 EnzymeBioSystems (OTCBB: ... along with the process of evaluating an enzyme ... in fighting tumors. In an effort to evaluate this ... with various contract research organizations to enlist their ... the use of an antitumor natural product called ...
(Date:9/23/2014)... Pa. , Sept. 23, 2014 The Pennsylvania ... drugs Sat., Sept. 27, as part of National Prescription ... no questions asked. Take-Back Day is a ... Enforcement Administration (DEA), aimed at encouraging the public to ... are prone to abuse and theft. From ...
(Date:9/23/2014)... , September 23, 2014 ... related disorders and increasing number of foreign and domestic ... probiotic in India   ... of the most high growth potential markets worldwide due ... consumers especially among the youth, changing food consumption patterns, ...
Breaking Medicine Technology:EnzymeBioSystems Announces Progress with an Enzyme Compound 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3
... LAKE, N.J., Nov. 9 Par Pharmaceutical Companies, Inc. ... extended the expiration date and increased the purchase price ... in which Par is offering to purchase, for cash, ... approximately 82.7%, of its outstanding 2.875% Senior Subordinated Convertible ...
... , NEW YORK, Nov. 9 MISSION Skincare®, the ... soccer professional Mia Hamm, and other world class athletes, ... beauty aisle of more than 5,000 CVS/pharmacy locations across ... face, body and sun care products, MISSION and CVS/pharmacy ...
Cached Medicine Technology:Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 2Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 3
(Date:9/23/2014)... California (PRWEB) September 23, 2014 Mel ... everything about cultivating, growing and harvesting marijuana. He is ... in the field and he’ll be leading a special ... 10:00 am to 5:00 pm at Oaksterdam University ... cultivation law, botany and nomenclature, harvesting and manicuring, and ...
(Date:9/23/2014)... Florida Hospital Zephyrhills officially celebrates ... Health Center on Wednesday, September 24. With more ... designed center offers a new level of personalized ... Women’s Health Center offers comprehensive women’s services including ... delivery through The Baby Place®, and breast care ...
(Date:9/23/2014)... Advisory , NIH TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ... , WHAT: , The National Institutes of ... assess the available scientific evidence on the long-term effectiveness ... Participants will be among the nation,s top experts in ... the country, as well as key NIH scientists who ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows all about ... can be treated. , A medically retired Army veteran, ... platoon sustained multiple attacks resulting in five casualties. After ... PTSD and honorably discharged from the Army. , “I ... myself from my friends and family,” recalled O’Farrell, who ...
(Date:9/23/2014)... 2014 Dr. Connie Casad has announced that ... new office space at 12200 Park Central Drive, Suite 200, ... will be Park Cities Aesthetics, Optimal Health and Wellness, her ... her move, Dr. Casad said, “The patients’ comfort and satisfaction ... we want them to always feel like their needs are ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Dr. Connie Casad Moving to New Office Location 2
... with improved survival odds, , SUNDAY, June 21 (HealthDay News) ... are more likely to survive these days than they would ... doctors are trying to puzzle out why heart attacks have ... doing right, and how to keep that trend headed in ...
... Implantable Cardioverter Defibrillator (ICD) have an ongoing risk of ... driving a car. Driving restrictions are imposed making ... consensus statement with recommendations for drivers with ICD,s was ... meeting, in Berlin, Germany on Sunday 21 June. ...
... approach would have the tremendous advantages of enhancing patient ... health staff to focus on medical emergencies," urged Professor ... and official spokesperson of the European Society of Cardiology ... advantage of being more cost effective for health care ...
... devastating to frail elderly and disabled Ohioans , ... Nursing Care Coalition, consisting of the three organizations representing ... than 80,000 frail elderly and disabled Ohioans, today expressed ... announced late Friday. , , "While we respect ...
... makes children fat , FRIDAY, June 19 (HealthDay News) ... fat, nor does living near a supermarket stocked with ... shows. , The study by Indiana University-Purdue University Indianapolis ... 60,000 children aged 3 to 18. They compared the ...
... that men shouldn,t take them with just this in mind ... such as aspirin and ibuprofen might help men avoid prostate ... caution men not to self-dose or to take more than ... can result. , "Our data suggest if men are taking ...
Cached Medicine News:Health News:Heart Attacks Less Often Fatal Today 2Health News:Heart Attacks Less Often Fatal Today 3Health News:Implanted defibrillators: New recommendations for drivers with ICDs 2Health News:EUROPACE raises remote monitoring profile 2Health News:EUROPACE raises remote monitoring profile 3Health News:Does Location Affect Kids' Weight? 2Health News:Painkillers May Be Good for the Prostate 2Health News:Painkillers May Be Good for the Prostate 3
... 210, Carl Zeiss has created a surgical microscope ... for ophthalmic surgery. Its wide range of uses ... and it offers new functions to improve depth ... integrated assistant's microscope the OPMI VISU 210 is ...
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
MONOJECT Brown Stopper...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
Medicine Products: